Precise Insights

Advanced Data and AI for Melanoma

On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.


See some of the 1000s of data elements we offer:

Structured Fields

Request a Demo


Structured Fields


Results from variety of patient tests


Oncology practice visits


Tumor-related observations plus vitals, biometrics, pain, and more


Surgeries, radiation, biopsies, imaging, chemotherapy, etc.


Start and end dates, brand vs. generic codes, dosage, duration, and cycles


Disease state, status, severity, and metastasis

Expert Abstraction

Request a Demo


Expert Abstraction


Biomarker testing, results, and timing

Disease Progression

Directly-observed measures of critical endpoints

Adverse Events

Different types of adverse responses


Classification into multiple categories

Enriched Data

Request a Demo


Enriched Data

Cost & Utilization

Adjudicated costs with linked claims data

Safety, Comorbidities

Pre-cancer and claims charge events

Specialty Pharmacy & Hub

Rx acquisition status details

Payer & Formulary

Drug tiers and coverage

Social Determinants

Social and physical environment factors

AI & Model-Based Insights

Request a Demo


AI & Model-Based Insights

Date of Metastasis

Rules-based imputation of date of metastasis

Metastatic Status

Imputation of missing data from unstructured notes

Date of Initial Dx

Imputation of index event

Line of Therapy

Regimen or progression-based drug classes

Patient Adherence

Identify root cause of product switching

Patient Acquisition

Predict factors driving patients’ brand decision

Request Data Count

Explore ConcertAI datasets to see how many patients are in your disease area and meet study criteria.


Research Studies

Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.

melanoma research study

Burden of Illness of Adjuvant Therapy for Advanced Melanoma

Stage I-III melanoma at high risk of progression is treated with the approved systemic adjuvant therapy. This study described treatment patterns, clinical outcomes, and healthcare costs among these patients.

See Full Study

Retrospective Observational Study

Patient Criteria
  • Adult patients with Stage I-III melanoma
  • Diagnosed between 1/2007 and 4/2013
  • Treated or untreated with systemic adjuvant therapy


Eligible patients


Patients treated with adjuvant systemic therapy


Patients treated with adjuvant systemic therapy

Received interferon/peginterferon therapy


Received interferon/peginterferon therapy


Median cost of interferon/peginterferon therapy


Total Cost


Months patients were treated with interferon


Months patients were treated with interferon

Patients remained on therapy at 1 year


Patients remained on therapy at 1 year


Real-world patients are older and sicker than those enrolled in pivotal clinical trials. Application of clinical trial findings to dissimilar populations may result in patient harm.

Value in Health, 2015